Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases

被引:18
|
作者
Hua, Fang [1 ]
Shi, Lingli [1 ]
Zhou, Peng [2 ,3 ]
机构
[1] Anhui Xinhua Univ, Pharm Sch, Hefei 230088, Peoples R China
[2] Anhui Univ Chinese Med, Sch Integrated Chinese & Western Med, Hefei 230012, Peoples R China
[3] Anhui Acad Chinese Med, Inst Integrated Chinese & Western Med, Hefei 230012, Peoples R China
基金
中国国家自然科学基金;
关键词
Phenols; Terpenoids; NLRP3; inflammasome; Cardiovascular diseases; NF-KAPPA-B; SIGNALING PATHWAY; MYOCARDIAL-INFARCTION; FERULIC ACID; INJURY; ACTIVATION; TRIPTOLIDE; POLYDATIN; CELASTROL; ORIDONIN;
D O I
10.1007/s10787-021-00918-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Inflammatory infiltration has been implicated in the pathogenesis of cardiovascular diseases (CVDs). The NLRP3 inflammasome is involved in the development of several types of CVDs, including myocardial infarction, myocardial ischemia-reperfusion damage, heart failure, atrial fibrillation, and hypertension. Inhibiting the activity of NLRP3 inflammasome can inhibit the progress of CVDs. However, there is no NLRP3 inflammasome inhibitor in clinic, and it is very important to find a safe and effective NLRP3 inhibitor. Phenols and terpenoids are naturally natural products that have many anti-inflammatory effects in CVDs by modulating the NLRP3 inflammatory pathway. Thus, 20 natural products from phenols and terpenoids for the treatment of cardiovascular disease based on the inhibition of NLRP3 inflammasome were summarized and screened. Docking results showed salvianolic acid B and ellagic acid in phenols, and oridonin and triptolide in terpenoids had a better binding activity with NLRP3, which can provide theoretical support for finding novel NLRP3 inflammasome inhibitors or lead compounds in the future.
引用
收藏
页码:137 / 147
页数:11
相关论文
共 50 条
  • [41] Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors
    Thapa, Pritam
    Upadhyay, Sunil P.
    Singh, Vikas
    Boinpelly, Varun C.
    Zhou, Jianping
    Johnson, David K.
    Gurung, Prajwal
    Lee, Eung Seok
    Sharma, Ram
    Sharma, Mukut
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS, 2023, 7
  • [42] Boron-Based Inhibitors of the NLRP3 Inflammasome
    Baldwin, Alex G.
    Rivers-Auty, Jack
    Daniels, Michael J. D.
    White, Claire S.
    Schwalbe, Carl H.
    Schilling, Tom
    Hammadi, Halah
    Jaiyong, Panichakorn
    Spencer, Nicholas G.
    England, Hazel
    Luheshi, Nadia M.
    Kadirvel, Manikandan
    Lawrence, Catherine B.
    Rothwell, Nancy J.
    Harte, Michael K.
    Bryce, Richard A.
    Allan, Stuart M.
    Eder, Claudia
    Freeman, Sally
    Brough, David
    CELL CHEMICAL BIOLOGY, 2017, 24 (11) : 1321 - +
  • [43] Cardioprotective effects of novel NLRP3 inflammasome inhibitors
    Comita, Stefano
    Pagliaro, Pasquale
    Penna, Claudia
    Bertinaria, Massimo
    Spyrakis, Francesca
    Gastaldi, Simone
    Boscaro, Valentina
    Gianquinto, Eleonora
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2022, 173 : S123 - S124
  • [44] Atranorin inhibits NLRP3 inflammasome activation by targeting ASC and protects NLRP3 inflammasome-driven diseases
    Wang, Hao-yu
    Lin, Xi
    Huang, Guan-gen
    Zhou, Rong
    Lei, Shu-yue
    Ren, Jing
    Zhang, Kai-rong
    Feng, Chun-lan
    Wu, Yan-wei
    Tang, Wei
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (08) : 1687 - 1700
  • [45] Atranorin inhibits NLRP3 inflammasome activation by targeting ASC and protects NLRP3 inflammasome-driven diseases
    Hao-yu Wang
    Xi Lin
    Guan-gen Huang
    Rong Zhou
    Shu-yue Lei
    Jing Ren
    Kai-rong Zhang
    Chun-lan Feng
    Yan-wei Wu
    Wei Tang
    Acta Pharmacologica Sinica, 2023, 44 : 1687 - 1700
  • [46] NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases
    Wang, Yucheng
    Liu, Xiaoxiao
    Shi, Hui
    Yu, Yong
    Yu, Ying
    Li, Minghui
    Chen, Ruizhen
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (01): : 91 - 106
  • [47] Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis
    Pinar, Anita A.
    Scott, Tara E.
    Huuskes, Brooke M.
    Caceres, Felipe E. Tapia
    Kemp-Harper, Barbara K.
    Samuel, Chrishan S.
    PHARMACOLOGY & THERAPEUTICS, 2020, 209
  • [48] Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)
    Zhang, Xiaolu
    Wang, Ziyu
    Zheng, Yujia
    Yu, Qun
    Zeng, Miao
    Bai, Liding
    Yang, Lin
    Guo, Maojuan
    Jiang, Xijuan
    Gan, Jiali
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2023, 51 (04)
  • [49] Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases
    Zhang, Xiangna
    Xu, Ana
    Lv, Jiahui
    Zhang, Qiuqiong
    Ran, Yingying
    Wei, Chao
    Wu, Jingde
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 185
  • [50] Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases
    Matthew S. J. Mangan
    Edward J. Olhava
    William R. Roush
    H. Martin Seidel
    Gary D. Glick
    Eicke Latz
    Nature Reviews Drug Discovery, 2018, 17 (9) : 688 - 688